Dataset Information
Hepatitis B serological markers and plasma DNA concentrations.
Ontology highlight
ABSTRACT: Objectives
To examine hepatitis B (HBV) serological markers and plasma DNA concentrations in a large group of untreated HBV/HIV-coinfected individuals in two sub-Saharan settings.Design
Baseline analysis of a randomized controlled trial.Methods
DART was a large trial of treatment monitoring practices in HIV-infected adults with advanced disease starting antiretroviral therapy at centres in Kampala or Entebbe, Uganda (n?=?2317) and Harare, Zimbabwe (n?=?999). HBV serological markers [antibody to HBV core antigen, HBV surface antigen (HBsAg), antibody to HBV surface antigen, HBV 'e' antigen (HBeAg), and antibody to hepatitis B 'e' antigen] and plasma HBV DNA viral load were measured retrospectively on stored baseline samples. Logistic regression was used to examine associations with baseline demographic and clinical factors.Results
The rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratio?=?1.54, P?ConclusionHigh rates of HBV coinfection were observed, highlighting the importance of ensuring that coinfected patients receive an antiretroviral regimen, whether first-line or not, that is active against both viruses.
SUBMITTER: Price H
PROVIDER: S-EPMC5414544 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Publications
Hepatitis B serological markers and plasma DNA concentrations.
AIDS (London, England) 20170501 8
<h4>Objectives</h4>To examine hepatitis B (HBV) serological markers and plasma DNA concentrations in a large group of untreated HBV/HIV-coinfected individuals in two sub-Saharan settings.<h4>Design</h4>Baseline analysis of a randomized controlled trial.<h4>Methods</h4>DART was a large trial of treatment monitoring practices in HIV-infected adults with advanced disease starting antiretroviral therapy at centres in Kampala or Entebbe, Uganda (n = 2317) and Harare, Zimbabwe (n = 999). HBV serologic ...[more]